Wells Fargo
SKYE icon

Wells Fargo’s Skye Bioscience SKYE Stock Holding History

Wells Fargo’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$1 – 7500
2025
Q4 		$1 Hold
1
– – ﹤0.01% 7085
2025
Q3 		$4 Sell
1
-375
-100% -$1.42K ﹤0.01% 6958
2025
Q2 		$1.57K Sell
376
-11,116
-97% -$23K ﹤0.01% 6243
2025
Q1 		$18.3K Buy
11,492
+293
+3% +$800 ﹤0.01% 5738
2024
Q4 		$31.7K Buy
11,199
+3,684
+49% +$15.4K ﹤0.01% 5628
2024
Q3 		$29.4K Buy
7,515
+243
+3% +$1.36K ﹤0.01% 5531
2024
Q2 		$58.2K Buy
+7,272
New +$86.3K ﹤0.01% 5238

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Wells Fargo's SKYE Position: Q1 2026 in Review

Wells Fargo sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 1 share — an estimated $1 sold.

Wells Fargo first reported a position in SKYE in Q2 2024 and held it in 7 quarters. The position peaked at $58.2K in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Wells Fargo reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 1 Skye Bioscience share in Q1 2026, an estimated $1.
  • Wells Fargo first reported a position in Skye Bioscience in Q2 2024 and held it in 7 quarters.
  • Wells Fargo's Skye Bioscience position peaked at $58.2K in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.